Document is current
Any future updates will be listed below
-
Authors
Pérez-Rubio, Alberto
Mestre-Ferrandiz, Jorge
López-Belmonte, Juan Luis
Diaz-Aguiló, Ariadna
Lorenzo-Herrero, Seila
Crespo, Carlos
-
Funding
Funding for this research was provided by:
Sanofi España
Axentiva Solutions
- License Information
-
More Information
Article History
Received: 16 November 2023
Accepted: 22 July 2024
First Online: 5 August 2024
Declarations
:
: Not applicable.
: Not applicable.
: AD and JLLB are employees of Sanofi and may hold shares and/or stock options in the company. SLH and CC are consultants of Axentiva Solutions, which received consultancy fees from Sanofi, Spain and, during the conduct of this study, from other pharmaceutical companies in unrelated projects. JMF reports having received a consulting fee from Axentiva Solutions for collaboration in this study and, during the conduct of this study, from other Sanofi funded projects related to RSV. AP reports having received funding from Sanofi for collaboration in this study and, during the conduct of this study, from other pharmaceutical companies in unrelated projects.
